Search research articles
Contact Us
Filters
Showing results (1071-1080 of 1,873) with videos related to
Page
of 188
Sort By:
JAMA
|
September 3, 2019
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction
James L Januzzi, Margaret F Prescott, Javed Butler, et al.
Circulation. Heart Failure
|
September 14, 2016
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy
Naoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
American Journal of Ophthalmology
|
February 27, 2007
Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgery
Renée Solomon, Eric D Donnenfeld, Henry D Perry, et al.
BMJ Open Diabetes Research & Care
|
December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia
Natalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
Hypertension (Dallas, Tex. : 1979)
|
December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction
Kota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Cardiology
|
April 27, 2022
Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community
Peder L Myhre, Brian Claggett, Bing Yu, et al.
European Heart Journal
|
March 21, 2023
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
Jawad H Butt, Mark C Petrie, Pardeep S Jhund, et al.
Cardiovascular Research
|
November 17, 2025
Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fraction
Shingo Matsumoto, Jawad H Butt, Kieran F Docherty, et al.
European Journal of Heart Failure
|
January 25, 2024
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial
Johann Bauersachs, Scott D Solomon, Stefan D Anker, et al.
JAMA Cardiology
|
September 27, 2023
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management
Ankeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Page
of 188
Search research articles
Search
Showing results (1071-1080 of 1,873) with videos related to
Sort By:
Page
of 188
JAMA
|
September 3, 2019
Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction
James L Januzzi, Margaret F Prescott, Javed Butler, et al.
Circulation. Heart Failure
|
September 14, 2016
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy
Naoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
American Journal of Ophthalmology
|
February 27, 2007
Methicillin-resistant Staphylococcus aureus infectious keratitis following refractive surgery
Renée Solomon, Eric D Donnenfeld, Henry D Perry, et al.
BMJ Open Diabetes Research & Care
|
December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia
Natalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
Hypertension (Dallas, Tex. : 1979)
|
December 28, 2020
Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction
Kota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Cardiology
|
April 27, 2022
Sex and Race Differences in N-Terminal Pro-B-type Natriuretic Peptide Concentration and Absolute Risk of Heart Failure in the Community
Peder L Myhre, Brian Claggett, Bing Yu, et al.
European Heart Journal
|
March 21, 2023
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
Jawad H Butt, Mark C Petrie, Pardeep S Jhund, et al.
Cardiovascular Research
|
November 17, 2025
Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fraction
Shingo Matsumoto, Jawad H Butt, Kieran F Docherty, et al.
European Journal of Heart Failure
|
January 25, 2024
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trial
Johann Bauersachs, Scott D Solomon, Stefan D Anker, et al.
JAMA Cardiology
|
September 27, 2023
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management
Ankeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Page
of 188